Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mainz Biomed N.V. - Ordinary Shares
(NQ:
MYNZ
)
0.3875
+0.0525 (+15.67%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Mainz Biomed N.V. - Ordinary Shares
< Previous
1
2
3
4
Next >
Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper
October 31, 2023
Almost half of Zöller-KipperGmbH’s employees in Germany participated in the screening program so far using ColoAlert®, Mainz Biomed’s user-friendly, at-home colorectal cancer (CRC) screening test
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations
October 26, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Presents Groundbreaking Results of ColoFuture Study
October 18, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark
October 11, 2023
Mainz Biomed team members will be available throughout the event at the Company’s booth located in Hall C, Stand C3-92
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit
October 05, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania
October 04, 2023
Strategic Collaboration Elevates Early Cancer Detection, Bringing State-of-the-Art Diagnostic Capabilities to Romanian Population
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology
September 27, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference
September 20, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%
September 13, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market
September 05, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference
August 29, 2023
Company Anticipates Read Outs of the Clinical Data from its EU and US Feasibility Studies this September and in Q4
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland
August 22, 2023
Strategic Partnership Aims to Revolutionize Cancer Screening and Enhance Healthcare Outcomes, Bringing Innovative Genetic Testing Solutions to Individuals Across Poland
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update
August 15, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom
August 01, 2023
Collaborative Partnership Strengthens Mainz Biomed's Mission to Combat Colorectal Cancer, Saving Lives through Advanced Diagnostics
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Announces Collaboration with Fugene Genetics in Israel
July 18, 2023
Israel has one of the highest screening compliance rates in the world with over one million people being screened each year
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Secures up to $50M in New Funding
June 29, 2023
Provides option to access capital to support commercial and clinical programs
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed to Attend ESMO World Congress on Gastrointestinal Cancer 2023 in Barcelona, Spain
June 28, 2023
The Company’s innovative CRC screening test will be showcased at booths 105A and 105B in cooperation with partner lab, Inicio-Instituto de Microecología
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Expands into Romania Through Partnership with Bioclinica
June 20, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Expands Commercial Footprint into Poland
May 31, 2023
Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today
Via
PressReach
Topics
Death
Exposures
Death
Being Overweight or Obese Increases Risk of Developing Colorectal Cancer
May 31, 2023
Maintaining a healthy weight is important for general health, but growing evidence reveals obesity’s role in the development of chronic illnesses and even deadly cancers. Obesity is one of the most...
Via
PressReach
Mainz Biomed Expands Commercial Footprint into Poland
May 31, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
BioNTech’s mRNA Vaccine Shows Early Potential Against Pancreatic Cancer
May 24, 2023
One of the most stubborn, deadly cancers is pancreatic cancer. What if individualized mRNA vaccinations could support the immune system’s defense? One of the deadliest forms of cancer around,...
Via
PressReach
Mainz Biomed Processes First Patients from Colorectal Cancer Screening Campaign Through its Corporate Health Portal in Partnership with Zöeller-Kipper
May 24, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 16, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
A New Groundbreaking Tool to Detect Colon Cancer Earlier
May 10, 2023
A novel blood test for detecting colon cancer, the third most lethal type of cancer in the US, has been created. The Colorectal Cancer Screening Blood Test can identify cancer at early stages. This...
Via
PressReach
Exposures
Product Safety
Colon Cancer Creeping Into Younger Adults – New R&D Uncovers Early Signs
May 10, 2023
Spots of blood after bowel movements, stomach aches, and protracted episodes of diarrhea may be symptoms of early-onset colorectal cancer, which is increasingly diagnosed in young adults who are...
Via
PressReach
Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlert
May 10, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
AI Tool Predicts Colon Cancer Survivorship and Response to Treatment
May 03, 2023
Harvard Medical School and National Cheng Kung University in Taiwan have designed an artificial intelligence (AI) algorithm to improve colorectal cancer prognosis and treatment options. The new...
Via
PressReach
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
New Artificial Intelligence Tool Can Diagnose Colon Cancer
May 03, 2023
A new artificial intelligence (AI) model developed by Harvard Medical School and Taiwan’s National Cheng Kung University could provide much-needed clarity to clinicians presenting prognoses and...
Via
PressReach
Topics
Artificial Intelligence
Death
Exposures
Artificial Intelligence
Death
Product Safety
Mainz Biomed Announces Addition of Eurofins GeLaMed to its Growing Network of Lab Partners
May 03, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.